%0 Journal Article
%A Bexte, Tobias
%A Reindl, Lisa Marie
%A Ullrich, Evelyn
%T Non-viral technologies can pave the way for CAR-NK cell therapy.
%J Journal of leukocyte biology
%V 114
%N 5
%@ 0741-5400
%C Hoboken, NJ
%I Wiley
%M DKFZ-2023-01349
%P 475-486
%D 2023
%Z 2023 Oct 26;114(5):475-486
%X Natural killer (NK) cells are a promising platform for cancer immunotherapy. NK cells have high intrinsic killing capability, and the insertion of a chimeric antigen receptor (CAR) can further enhance their anti-tumor potential. In first human trials, CAR-NK cells demonstrated strong clinical activity without therapy-induced side effects. The applicability of NK cells as an 'off-the-shelf' product makes them highly attractive for gene-engineered cell-therapies. Traditionally, viral transduction has been used for gene-editing; however, the use of viral vectors remains a safety concern and is associated with high costs and regulatory requirements. Here, we review the current landscape of non-viral approaches for CAR-NK cell generation, which include transfection of vector particles and electroporation of mRNA and DNA vectors resulting in transient gene-modification and CAR expression. In addition, using non-viral transposon technologies, NK cells can be stably modified ensuring long-lasting CAR expression. Finally, we discuss CRISPR/Cas9 tools to edit key genes for NK cell functionality.
%K CAR (Other)
%K CRISPR (Other)
%K electroporation (Other)
%K mRNA (Other)
%K natural killer cell (Other)
%K non-viral (Other)
%K transposon (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37403203
%R 10.1093/jleuko/qiad074
%U https://inrepo02.dkfz.de/record/277341